SCHEMBL7211356

SCHEMBL7211356

N[C@@H](CCc1nc2ccccc2[nH]1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.62
KDM4E B2RXH2 1/20 0.57
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
POLB P06746 1/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
PDE10A Q9Y233 1/20 0.54
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.51
MAPT P10636 1/20 0.51
GAA P10253 1/20 0.51
PIN1 Q13526 2/20 0.50
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD3 P35462 1/20 0.49
TSHR P16473 1/20 0.49
RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5325374 1.00 CHRM1 (0.62) CHRM1KDM4ECYP1A2CYP2C9POLB
SCHEMBL7267155 0.85 PIN1 (0.59) CHRM1KDM4ECYP1A2CYP2C9POLB
SCHEMBL30042883 0.85 PIN1 (0.59) CHRM1KDM4ECYP1A2CYP2C9POLB
SCHEMBL5280678 0.85 PIN1 (0.59) CHRM1KDM4ECYP1A2CYP2C9POLB
SCHEMBL5875699 0.85 PIN1 (0.59) CHRM1KDM4ECYP1A2CYP2C9POLB
SCHEMBL27508042 0.81 CYP1A2 (0.54) CHRM1KDM4ECYP1A2CYP2C9POLB
SCHEMBL21101235 0.81 SLC40A1 (0.49) CHRM1KDM4EPOLBRAB9AHTT
SCHEMBL22639894 0.79 POLB (0.58) CHRM1KDM4ECYP1A2CYP2C9POLB
Procodazole SCHEMBL838841 0.77 CHRM1 (1.00) CHRM1KDM4ECYP1A2CYP2C9POLB
Procodazole SCHEMBL29404024 0.77 CHRM1 (1.00) CHRM1KDM4ECYP1A2CYP2C9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10828281-B2 Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) 2020-11-10 US disclosed
WO-2017189868-A1 SERINE REPLACEMENT POLYMYXIN ANALOGUES USEFUL AS ANTIBIOTIC POTENTIATORS SPERO OPCO (US) 2017-11-02 WO disclosed
US-6620820-B2 Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies HOECHST AKTIENGESELLSCHAFT (DE) 2003-09-16 US disclosed
US-20020119999-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors HOECHST AKTIENGESELLSCHAFT 2002-08-29 US disclosed
US-6218415-B1 THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES HOECHST AKTIENGESELLSCHAFT (DE) 2001-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10828281-B2 Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect VIM, MATR3, TP53 CHRM1 2732/4885KDM4E 4343/4885CYP1A2 3886/4885
US-20020119999-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors ADGRF1, CALCR, SOST CHRM1 1287/4885KDM4E 4004/4885CYP1A2 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.